Most hematogenous candidiasis originates from endogenous host flora. The impact of clinically prominent Candida colonization on short-term mortality (р14 weeks) was prospectively studied in 193 hospitalized patients from 1998 to 1999. Clinically prominent colonization included yeasts isolated from all sterile body sites and Ͼ50 colonies of Candida from non-sterile sites. Fourteen (7.1%) patients were granulocytopenic (ANC р100/l). Nineteen (9.8%) had undergone marrow transplantation, 26 (13.5%) had a hematologic malignancy and 129 (66.5) had non-hematologic cancer. Candida isolates (216) were collected form 210 specimens. Fifty-three (27.5%) patients died; 25 (19.4%) with solid tumors, compared to 16 (61.5%) with hematological malignancy, and 11 (57.9%) BMT recipients (P Ͻ 0.001). No deaths were seen in patients with AIDS, and one (7.7%) in a patient with a benign condition (P Ͻ 0.001). Twenty-six (29.2%) patients with respiratory tract, 13 (23.2%) with gastrointestinal tract, and three (14.3%) with genitourinary tract colonization died. In patients with multiple-site colonization, mortality was significantly higher (45.5%) (P Ͻ 0.05). Mortality was higher in patients with C. glabrata (52.9%) and C. krusei (75%) colonization than with C. albicans (24.1%) (P Ͻ 0.025). This study shows that patients with hematologic cancer and recipients of marrow transplant with Candida colonization of multiple body sites, and colonization with C. glabata or C. krusei have poor survival. Bone Marrow Transplantation (2002) 30, 931-935.
Systemic candidiasis is a serious complication in patients undergoing treatment for cancer. 1, 2 Most invasive Candida infections originate from endogenous host microflora. 3, 4 Yeast colonization of the implantable and semi-implantable indwelling intravascular devices may also serve as a focus for hematogenous invasion and persistent infection. 5 Colonization due to the non-albicans Candida species is rising, 6 and in recent years the significant increase in bloodstream invasion due to C. glabrata and C. krusei, 7, 8 especially in 'at risk' allogeneic marrow transplantation recipients is of serious concern. 9 In oncology patients, systemic infections due to frequently isolated non-albicans Candida such as C. glabrata, C. tropicalis and C. krusei are also associated with higher mortality. [10] [11] [12] We performed a detailed prospective evaluation of prominent Candida colonization with respect to body sites, yeast species, host factors and impact on short-term survival among hospitalized patients at a comprehensive cancer center.
Patients and methods

Study design
All hospitalized patients with Candida isolates were evaluated prospectively between 1 July 1998 and 1 April 1999 at Memorial Sloan-Kettering Cancer Center in New York. All fungal cultures were initially screened and processed at The Microbiology Laboratory, Division of Clinical Laboratories, Memorial Sloan-Kettering Cancer Center. Demographic information and laboratory data were retrieved from patients' chart and computerized hospital data systems. All patients with a clinically prominent colonization of Candida were included and those with confirmed or probable infection were excluded. More than one Candida isolate from a single patient was included if the specimen was obtained from separate body sites or if multiple Candida species were identified. Each patient was followed for 14 weeks after the initial isolation of Candida.
Definitions
Clinically prominent colonization was defined as the presence of Candida from a sterile body site specimen or Ͼ50 colonies of Candida from nonsterile sources. All Candida isolates from blood cultures and those with the potential for invasion such as intra-abdominal, pelvic, bone, and joint collections were excluded. Short-term mortality was defined as death within 14 weeks after the initial Candida culture was obtained.
Microbiology
Identification of Candida species was performed by methods described previously. 6 Five to ten yeast colonies were obtained from the primary culture and transported on trypticase soy agar slants (Becton Dickinson Microbiology Systems, Cockeysville, MD, USA) for species reidentification (under code) at the New York State Department of Health Mycology Laboratory.
Statistical analysis
The Chi-square test was used for comparing categorical variables, a two-sided P value of р0.05 was considered statistically significant.
Results
Patient characteristics
These are shown in Table 1 .
Outcome related to cancer (Table 1) : Fifty-three patients died during the study period. Overall mortality in the solidorgan cancer group was 19.4%, compared to 61.5% in patients with an underlying hematological cancer (P Ͻ 0.001). Similarly, a high short-term mortality was also observed in the marrow transplant group (57.9%; P Ͻ 0.001). There were no deaths in patients with AIDS, and only a single patient (6.7%) in the benign disease group died.
Outcome related to site of colonization (Table 2) : Among 171 patients with Candida colonization of a single body site, 43 died (25.1%). Twenty-two had multiple site colonization, mostly upper and lower respiratory tract involvement. Short-term survival in this group was poor (mortality 45.5%; P Ͻ 0.05). Mortality in patients with respiratory tract colonization was slightly higher (29.2%) than gastrointestinal tract colonization (23.2%). In patients with candiduria, short-term mortality was 20% (P Ͼ 0.5).
Outcome related to Candida species (Table 3) : Two hundred and sixteen Candida isolates were obtained from 210 specimens. C. albicans was the most common (69.4%). Among 66 non-albicans Candida, half were C. glabrata, eight (12.1%) C. parapsilosis, seven (10.6%) C. tropicalis, and six (9.1%) C. krusei. A single Candida species was isolated from 171 patients and 22 had multiple yeast species colonization. Mortality in these groups did not differ significantly (25.1% and 18.2% respectively; P Ͼ 0.5). Deaths in patients with C. albicans either with single site (20.8%) or multiple-site (53.8%) colonization were significantly lower, compared to short-term mortality in individuals with C. glabrata colonization of a single site (46.7%) and multiple sites (100%) (P Ͻ 0.025). Similarly, two-thirds of patients with C. krusei colonization died (75%; P Ͻ 0.025).
Discussion
Invasive Candida infections are significantly higher in patients with prior yeast colonization compared to individuals with no evidence of colonization despite profound immune suppression. 13 During the last decade, the nearuniversal use of fluconazole for prophylaxis in marrow transplant recipients has been linked to a significant rise in colonization due to C. glabrata [14] [15] [16] [17] and C. krusei, 18 and subsequent bloodstream invasion. [8] [9] [10] 17, 19 Since prior colonization has been established as an important risk factor for invasive candidiasis in the susceptible host, 20 a significant association between C. glabrata, or C. krusei colonization and poor short-term survival in this study was expected (P Ͻ 0.025) ( Table 3) . 
Bone Marrow Transplantation
Patients undergoing blood and marrow transplantation are at a higher risk of systemic invasion due to Candida species. 21 Important risk factors for candidemia in adult BMT patients include colonization with Candida, human cytomegalovirus disease, and bacteremia. 9, 17, 19 As mentioned earlier, most infections originate from endogenous host reservoirs, and the orointestinal tract is though to be the principle source for hematogenous invasion, especially in critically ill patients at risk of fungal dissemination. 22, 23 Experiments using animal models suggest that high-grade, sustained Candida gastrointestinal tract colonization increases the risk of systemic yeast dissemination and prior to bloodstream invasion a disruption of the mucosal barrier was consistently found among immunosuppressed animals. 24, 25 We report no statistically significant difference in the impact of colonization of either respiratory, orointestinal or urinary tract on short-term survival (P Ͼ 0.5). As expected, mortality in patients with candiduria was lowest when compared to the other two groups (Table 2) . 26 On the other hand, the significantly higher mortality (45.5%) in patients with multiple-site colonization, especially upper and lower respiratory tract involvement was interesting and probably relates to a higher 'yeast burden' ( Table 2 ; P Ͻ 0.05). Alternatively, this may represent previously undiagnosed lower respiratory tract infections due to Candida. In critically ill, non-granulocytopenic patients on mechanical ventilation Candida was isolated from the lower respiratory tract in nearly half, while Candida pneumonia was seen in only 8% during a recent prospective report. 27 Similarly in this study, we do not suspect that invasive pulmonary disease due to Candida was related to the increased short-term mortality in non-neutropenic patients with lower respiratory tract colonization.
In conclusion, patients undergoing blood or marrow transplantation who have prominent colonization with Candida species, especially those with multiple body site involvement, and presence of C. glabrata or C. krusei may be considered for targeted strategies designed to reduce 'yeast burden'. The current use of fluconazole appears to be effective in preventing C. albicans fungemia in recipients of blood and marrow transplantation. 9, [17] [18] [19] [20] However, strategies to reduce breakthrough infection due to nontriazole susceptible Candida species are at present unreliable. Methods suggested recently include: (1) targeted antifungal prophylaxis, especially trials of the upcoming broad-spectrum triazoles, or pneumocandin/echinocandins; (2) enforcement of a stringent protective environment, which appears to reduce colonization of the upper respiratory and orointestinal tracts; 28 (3) selective decontamination of the orointestinal tract; 29 and (4) novel strategies employing anti-Candida antibodies 30 which require further clinical investigation.
